Please assess the completion status of the following clinical trial:

Trial Title: A Study of RVT-1401 in Myasthenia Gravis (MG) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female ≥ 18 years of age.~2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator.~3. QMG score ≥12 at Screening and Baseline.~Other, more specific inclusion criteria are defined in the protocol.~Exclusion Criteria:~1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing.~2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening.~3. Thymectomy performed \< 12 months prior to screening.~4. Total IgG level \<6 g/L (at screening).~5. Absolute neutrophil count \<1500 cells/mm3(at screening).~Other, more specific exclusion criteria are defined in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regimen A (Type: EXPERIMENTAL): RVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
- Regimen B (Type: EXPERIMENTAL): RVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).